Cargando…
Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
Haapaniemi et al address the issues raised by Brown et al and discuss several differences between the analyses performed by the two groups. [Image: see text]
Autores principales: | Haapaniemi, Emma, Botla, Sandeep, Persson, Jenna, Schmierer, Bernhard, Taipale, Jussi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686827/ https://www.ncbi.nlm.nih.gov/pubmed/31464368 http://dx.doi.org/10.15252/msb.20199059 |
Ejemplares similares
-
CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019) -
CRISPR/Cas9 screening using unique molecular identifiers
por: Schmierer, Bernhard, et al.
Publicado: (2017) -
Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
por: Stolte, Björn, et al.
Publicado: (2018) -
Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12
por: Mäkinen, Netta, et al.
Publicado: (2016) -
Rapid genome editing by CRISPR-Cas9-POLD3 fusion
por: Reint, Ganna, et al.
Publicado: (2021)